A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel- a Systematic Review
May 1, 2014, 00:00 AM
10.1016/j.jval.2014.03.409
https://www.valueinhealthjournal.com/article/S1098-3015(14)00460-4/fulltext
Section Title :
Cancer
Section Order :
1458
First Page :
A70
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00460-4&doi=10.1016/j.jval.2014.03.409